S. H. Sinclair, Macular retinal capillary hemodynamics in diabetic patients

, Ophthalmology, vol.98, issue.10, pp.1580-1586, 1991.

D. Weinberger, S. Fink-cohen, D. D. Gaton, E. Priel, and Y. Yassur, Non-retinovascular leakage in diabetic maculopathy, Br J Ophthalmol. août, vol.79, issue.8, pp.728-759, 1995.

I. Fukushima, D. S. Mcleod, and G. A. Lutty, Intrachoroidal microvascular abnormality: a previously unrecognized form of choroidal neovascularization, Am J Ophthalmol, vol.124, issue.4, pp.473-87, 1997.

A. Bringmann, T. Pannicke, J. Grosche, M. Francke, P. Wiedemann et al., Müller cells in the healthy and diseased retina, Prog Retin Eye Res. juill, vol.25, issue.4, pp.397-424, 2006.

M. Hollborn, S. Dukic-stefanovic, T. Pannicke, E. Ulbricht, A. Reichenbach et al., Expression of aquaporins in the retina of diabetic rats, Curr Eye Res. sept, vol.36, issue.9, pp.850-856, 2011.

D. M. Nathan, D. For-the, and . Group, The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Study at 30 Years: Overview. Diabetes Care, janv, vol.37, issue.1, pp.9-16, 2014.

N. H. White, W. Sun, P. A. Cleary, R. P. Danis, M. D. Davis et al., Prolonged effect of intensive therapy on the risk of retinopathy complications in patients with type 1 diabetes mellitus: 10 years after the Diabetes Control and Complications Trial, Arch Ophthalmol Chic Ill, vol.126, issue.12, pp.1707-1722, 1960.

B. Fullerton, K. Jeitler, M. Seitz, K. Horvath, A. Berghold et al., Intensive glucose control versus conventional glucose control for type 1 diabetes mellitus, Cochrane Database Syst Rev. 14 févr, issue.2, p.9122, 2014.

J. Yau, S. L. Rogers, R. Kawasaki, E. L. Lamoureux, J. W. Kowalski et al., Global prevalence and major risk factors of diabetic retinopathy, Diabetes Care. mars, vol.35, issue.3, pp.556-64, 2012.

C. Creuzot-garcher, OEdèmes maculaires -Rapport SFO, vol.676, 2016.

, Early Treatment Diabetic Retinopathy Study report number 1. Early Treatment Diabetic Retinopathy Study research group, Arch Ophthalmol Chic Ill, vol.103, issue.12, pp.1796-806, 1960.

D. R. Senger, S. J. Galli, A. M. Dvorak, C. A. Perruzzi, V. S. Harvey et al., Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid, Science. 25 févr, vol.219, issue.4587, pp.983-988, 1983.

D. T. Connolly, D. M. Heuvelman, R. Nelson, J. V. Olander, B. L. Eppley et al., Tumor vascular permeability factor stimulates endothelial cell growth and angiogenesis, J Clin Invest, vol.84, issue.5, pp.1470-1478, 1989.

N. Ferrara and W. J. Henzel, Pituitary follicular cells secrete a novel heparin-binding growth factor specific for vascular endothelial cells, Biochem Biophys Res Commun. 15 juin, vol.161, issue.2, pp.851-859, 1989.

H. Funatsu, H. Yamashita, T. Ikeda, T. Mimura, S. Eguchi et al., Vitreous levels of interleukin-6 and vascular endothelial growth factor are related to diabetic macular edema, Ophthalmology. sept, vol.110, issue.9, pp.1690-1696, 2003.

D. A. Antonetti, A. J. Barber, L. A. Hollinger, E. B. Wolpert, and T. W. Gardner, Vascular endothelial growth factor induces rapid phosphorylation of tight junction proteins occludin and zonula occluden 1. A potential mechanism for vascular permeability in diabetic retinopathy and tumors, J Biol Chem. 13 août, vol.274, issue.33, pp.23463-23470, 1999.

S. Suarez, G. W. Mccollum, C. A. Bretz, R. Yang, M. E. Capozzi et al., Modulation of VEGFinduced retinal vascular permeability by peroxisome proliferator-activated receptor?/?. Invest Ophthalmol Vis Sci, vol.55, pp.8232-8272, 2014.

V. H. Gonzalez, J. Campbell, N. M. Holekamp, S. Kiss, A. Loewenstein et al., Early and Long-Term Responses to Anti-Vascular Endothelial Growth Factor Therapy in Diabetic Macular Edema: Analysis of Protocol I Data, Am J Ophthalmol. déc, vol.172, pp.72-81, 2016.

T. W. Gardner, D. A. Antonetti, A. J. Barber, K. F. Lanoue, and S. W. Levison, Diabetic retinopathy: more than meets the eye, Surv Ophthalmol. déc, vol.47, issue.2, pp.253-262, 2002.

J. E. Sears and G. Hoppe, Triamcinolone acetonide destabilizes VEGF mRNA in Müller cells under continuous cobalt stimulation, Invest Ophthalmol Vis Sci, vol.46, issue.11, pp.4336-4377, 2005.

C. Attar, M. Acheampong, A. A. Robinson, M. R. Whitcup, S. M. Kuppermann et al., Pharmacokinetics and pharmacodynamics of a sustained-release dexamethasone intravitreal implant, Invest Ophthalmol Vis Sci. 5 janv, vol.52, issue.1, pp.80-86, 2011.

F. Fasce, M. Battaglia-parodi, K. A. Knutsson, A. Spinelli, P. Mauceri et al., Accidental injection of dexamethasone intravitreal implant in the crystalline lens, Acta Ophthalmol (Copenh). juin, vol.92, issue.4, pp.330-331, 2014.

J. Coca-robinot, B. Casco-silva, F. Armadá-maresca, and J. García-martínez, Accidental injections of dexamethasone intravitreal implant (Ozurdex) into the crystalline lens, Eur J Ophthalmol. août, vol.24, issue.4, pp.633-639, 2014.

A. Berarducci, I. S. Sian, and R. Ling, Inadvertent dexamethasone implant injection into the lens body management, Eur J Ophthalmol. août, vol.24, issue.4, pp.620-622, 2014.

R. Agrawal, G. Fernandez-sanz, S. Bala, and P. Addison, Desegmentation of Ozurdex implant in vitreous cavity: report of two cases, Br J Ophthalmol. juill, vol.98, issue.7, pp.961-964, 2014.

P. Rishi, G. Mathur, and E. Rishi, Fractured Ozurdex TM implant in the vitreous cavity, Indian J Ophthalmol. juill, vol.60, issue.4, pp.337-345, 2012.

R. Roy and S. Hegde, Split Ozurdex implant: a caution, Can J Ophthalmol J Can Ophtalmol. févr, vol.48, issue.1, pp.15-16, 2013.

O. Donmez, M. Parlak, A. Yaman, and A. O. Saatci, Splitting of a Dexamethasone Implant (Ozurdex) following the Injection, Case Rep Ophthalmol Med, p.247949, 2013.

R. K. Maturi, A. Pollack, H. S. Uy, M. Varano, A. Gomes et al., INTRAOCULAR PRESSURE IN PATIENTS WITH DIABETIC MACULAR EDEMA TREATED WITH DEXAMETHASONE INTRAVITREAL IMPLANT IN THE 3-YEAR MEAD STUDY, Retina Phila Pa. juin, vol.36, issue.6, pp.1143-52, 2016.

G. Soubrane and F. Behar-cohen, Micro-implant d'acétonide de fluocinolone (ILUVIEN®) pour l'oedème maculaire diabétique chronique, J Fr Ophtalmol. févr, vol.38, issue.2, pp.159-67, 2015.

M. Bolz, U. Schmidt-erfurth, G. Deak, G. Mylonas, K. Kriechbaum et al., Optical coherence tomographic hyperreflective foci: a morphologic sign of lipid extravasation in diabetic macular edema, Ophthalmology. mai, vol.116, issue.5, pp.914-934, 2009.

C. Busch, D. Zur, S. Fraser-bell, I. Laíns, A. R. Santos et al., Shall we stay, or shall we switch? Continued anti-VEGF therapy versus early switch to dexamethasone implant in refractory diabetic macular edema, Acta Diabetol. août, vol.55, issue.8, pp.789-96, 2018.

W. M. Amoaku, U. Chakravarthy, R. Gale, M. Gavin, F. Ghanchi et al., Defining response to anti-VEGF therapies in neovascular AMD, Eye Lond Engl. juin, vol.29, issue.6, pp.721-752, 2015.

A. R. Santos, M. Â. Costa, C. Schwartz, D. Alves, J. Figueira et al., OPTICAL COHERENCE TOMOGRAPHY BASELINE PREDICTORS FOR INITIAL BEST-CORRECTED VISUAL ACUITY RESPONSE TO INTRAVITREAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR TREATMENT IN EYES WITH DIABETIC MACULAR EDEMA: The CHARTRES Study, Retina Phila Pa. juin, vol.38, issue.6, pp.1110-1119, 2018.

V. Castro-navarro, E. Cervera-taulet, C. Navarro-palop, L. Hernández-bel, C. Monferrer-adsuara et al., Analysis of anatomical biomarkers in subtypes of diabetic macular edema refractory to anti-vascular endothelial growth factor treated with dexamethasone implant, Eur J Ophthalmol. 4 mars, p.1120672119834182, 2019.

S. H. Radwan, A. Z. Soliman, J. Tokarev, L. Zhang, F. J. Van-kuijk et al., Association of Disorganization of Retinal Inner Layers With Vision After Resolution of Center-Involved Diabetic Macular Edema, JAMA Ophthalmol. juill, vol.133, issue.7, pp.820-825, 2015.

V. Bonfiglio, M. Reibaldi, A. Pizzo, A. Russo, I. Macchi et al., Dexamethasone for unresponsive diabetic macular oedema: optical coherence tomography biomarkers

, Acta Ophthalmol (Copenh). juin, vol.97, issue.4, pp.540-544, 2019.

D. Zur, M. Iglicki, C. Busch, A. Invernizzi, M. Mariussi et al., OCT Biomarkers as Functional Outcome Predictors in Diabetic Macular Edema Treated with Dexamethasone Implant, Ophthalmology, vol.125, issue.2, pp.267-75, 2018.

N. Rayess, E. Rahimy, G. Ying, N. Bagheri, A. C. Ho et al., Baseline choroidal thickness as a predictor for response to anti-vascular endothelial growth factor therapy in diabetic macular edema, Am J Ophthalmol. janv, vol.159, issue.1, pp.1-3, 2015.

V. Bonfiglio, M. Reibaldi, A. Pizzo, A. Russo, I. Macchi et al., Dexamethasone for unresponsive diabetic macular oedema: optical coherence tomography biomarkers

, Acta Ophthalmol (Copenh). juin, vol.97, issue.4, pp.540-544, 2019.

I. P. Chatziralli, T. N. Sergentanis, S. Sivaprasad, . Hyperreflective, . An et al., Retina Phila Pa. déc, vol.36, issue.12, pp.2319-2347, 2016.

B. S. Gerendas, S. Prager, G. Deak, C. Simader, J. Lammer et al., Predictive imaging biomarkers relevant for functional and anatomical outcomes during ranibizumab therapy of diabetic macular oedema, Br J Ophthalmol, vol.102, issue.2, pp.195-203, 2018.

G. S. Tan, N. Cheung, R. Simó, G. Cheung, and T. Y. Wong, Diabetic macular oedema, Lancet Diabetes Endocrinol, vol.5, issue.2, pp.143-55, 2017.

P. Mitchell, F. Bandello, U. Schmidt-erfurth, G. E. Lang, P. Massin et al., The RESTORE study: ranibizumab monotherapy or combined with laser versus laser monotherapy for diabetic macular edema, Ophthalmology. avr, vol.118, issue.4, pp.615-640, 2011.

J. Korobelnik, C. Lu, T. A. Katz, D. S. Dhoot, A. Loewenstein et al., Effect of Baseline Subretinal Fluid on Treatment Outcomes in VIVID-DME and VISTA-DME Studies, Ophthalmol Retina. août, vol.3, issue.8, pp.663-672, 2019.

P. Romero-aroca, M. Baget-bernaldiz, A. Pareja-rios, M. Lopez-galvez, R. Navarro-gil et al., Diabetic Macular Edema Pathophysiology: Vasogenic versus Inflammatory, J Diabetes Res, p.2156273, 2016.

D. S. Boyer, Y. H. Yoon, R. Belfort, F. Bandello, R. K. Maturi et al., Three-year, randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with diabetic macular edema, Ophthalmology. oct, vol.121, issue.10, pp.1904-1918, 2014.

A. Hernández-martínez, P. Delgado, E. , S. Silva, G. et al., Early versus late switch: How long should we extend the anti-vascular endothelial growth factor therapy in unresponsive diabetic macular edema patients?, Eur J Ophthalmol. 16 mai, 2019.

J. Lee, B. G. Moon, A. R. Cho, and Y. H. Yoon, Optical Coherence Tomography Angiography of DME and Its Association with Anti-VEGF Treatment Response, Ophthalmology, vol.123, issue.11, pp.2368-75, 2016.

D. Network, W. Committee, L. P. Aiello, R. W. Beck, N. M. Bressler et al., Rationale for the diabetic retinopathy clinical research network treatment protocol for center-involved diabetic macular edema, Ophthalmology. déc, vol.118, issue.12, pp.5-14, 2011.

M. Iglicki, C. Busch, D. Zur, M. Okada, M. Mariussi et al., DEXAMETHASONE IMPLANT FOR DIABETIC MACULAR EDEMA IN NAIVE COMPARED WITH REFRACTORY EYES: The International Retina Group Real-Life 24-Month Multicenter Study. The IRGREL-DEX Study, Retina Phila Pa. janv, vol.39, issue.1, pp.44-51, 2019.

S. Guigou, C. Hajjar, E. Parrat, P. Y. Merite, S. Pommier et al.,

, J Fr Ophtalmol. juin, vol.37, issue.6, pp.480-485, 2014.

, Résumé Introduction : L'oedème maculaire diabétique (OMD) est une cause majeure de baisse de l'acuité visuelle dans les pays développé. Plusieurs molécules sont disponibles : les anti-VEGFs en première intention, et l'implant intravitréen (Ozurdex®) de dexaméthasone en seconde

. Vegfs, existe-t-il des critères incitant à un switch précoce vers l'Ozurdex® plutôt qu'à un maintien sous anti-VEGF ?

M. Matériel, Analyse rétrospective observationnelle de tous les oedème maculaire diabétique résistants aux anti-VEGFs ayant bénéficié d'injection(s) d'Ozurdex® avec suivi sur 6 mois

, Résultats : 32 yeux ont été inclus. A 6 mois, nous retrouvons un coefficient de corrélation ? : de -8, vol.9

, 17,0 ; -1,4) en multivariée entre la présence d'une désorganisation des couches rétiniennes internes (DRIL) et l'acuité visuelle, vol.95

, 141,7) en multivariée entre la présence de points hyper-réflectifs (HRD) et l'épaisseur maculaire centrale, vol.5, pp.95-467

, ) en analyse multivariée entre la catégorie OEdème Maculaire Central et l'épaisseur maculaire central. Conclusion : Cette étude confirme l'association des DRIL à la mauvaise récupération visuelle, et des HRD à la diminution du CMT à 6 mois chez les patients traités par Ozurdex® pour un OMD